Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors

Chan Shen (), Arvind Dasari, Dian Gu, Yiyi Chu, Shouhao Zhou, Ying Xu, Daniel Halperin, Shuangshuang Fu, James C. Yao and Ya-Chen Shih
Additional contact information
Chan Shen: The University of Texas MD Anderson Cancer Center
Arvind Dasari: The University of Texas MD Anderson Cancer Center
Dian Gu: The University of Texas MD Anderson Cancer Center
Yiyi Chu: The University of Texas MD Anderson Cancer Center
Shouhao Zhou: The University of Texas MD Anderson Cancer Center
Ying Xu: The University of Texas MD Anderson Cancer Center
Daniel Halperin: The University of Texas MD Anderson Cancer Center
Shuangshuang Fu: The University of Texas Health Science Center in Houston
James C. Yao: The University of Texas MD Anderson Cancer Center

PharmacoEconomics, 2018, vol. 36, issue 8, No 11, 1005-1013

Abstract: Abstract Background The incidence and prevalence of neuroendocrine tumors (NETs) have been steadily rising. NETs can arise in various parts of the body and have distinct pathogenesis, clinical manifestations, treatment, and survival compared to other neoplasms. The magnitude of the economic burden of NETs is largely unknown. This study aimed to estimate the cost of illness for NETs among elderly patients based on a large amount of observational data. Methods We estimated the direct medical costs by phase of care using the Surveillance, Epidemiology, and End Results-Medicare data, including claims from January 1, 2002 through to December 31, 2012. Patients’ care was categorized into three phases: initial phase (first year after diagnosis), terminal phase (last year of life), and continuing phase (the period between). We estimated the cost of illness by calculating the difference in medical costs between NET patients and a matched sample from a non-cancer control group. Results Our study sample included 8409 elderly NET patients in the initial phase, 9218 patients in the continuing phase, and 7897 in the terminal phase. The mean cost of care for the initial phase was $46,462 in 2016 US dollars; mean cost of care for the terminal phase with a cancer-related death was $122,702; while the mean cost of care for the continuing phase was $10,457. The mean 5-year cost was $87,079. Conclusions This population-based study showed that NET patients had substantial continuing phase costs and 5-year costs. Among elderly NET patients, those with pancreas as the primary cancer site had the highest costs.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-018-0656-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:36:y:2018:i:8:d:10.1007_s40273-018-0656-z

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-018-0656-z

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().